Benjamin Lockshin, MD, FAAD, offers a forward-looking synthesis of how psoriasis care has evolved toward holistic, personalized management—and where advances in oral therapies, biomarker-guided selection, and equitable access will define the next era of treatment.
Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how clinicians use primary versus secondary loss of efficacy to guide biologic sequencing decisions across IL-23 and IL-17 classes.
Benjamin Lockshin, MD, FAAD, reviews real-world persistence data for tildrakizumab, discussing the interplay of clinical efficacy, insurance coverage, and buy-and-bill reimbursement in driving long-term treatment durability—particularly among Medicare and Medicaid patients.
Benjamin Lockshin, MD, FAAD, examines how geographic variation in psoriasis patient characteristics and biologic prescribing reflects a complex interplay of insurance access, formulary structure, practice site demographics, and regional socioeconomic factors.
Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient counseling, and versatility in managing psoriatic comorbidities.
Nonsteroidal topicals like roflumilast are enabling proactive, long-term psoriasis control across a broad range of patients, reducing reliance on corticosteroids and minimizing the need for systemic escalation.
Real-world evidence complements clinical trial data by capturing how psoriasis therapies perform across diverse patient populations and treatment contexts in everyday practice.
